Skip to main content
Netramark Holdings Inc. logo

Netramark Holdings Inc. — Investor Relations & Filings

Ticker · AIAI ISIN · CA64119M1059 LEI · 391200VOK8WHERIX0Q06 CSE Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 336 across all filing types
Latest filing 2022-08-23 Regulatory Filings
Country CA Canada
Listing CSE AIAI

About Netramark Holdings Inc.

https://www.netramark.com/

Netramark Holdings Inc. develops and deploys advanced Artificial Intelligence (AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry, focusing on optimizing clinical trial design and outcomes. Its core product, NetraAI, is an AI platform powered by the proprietary Attractor AI algorithm. NetraAI analyzes complex, multimodal clinical trial datasets to uncover hidden patient correlations and causal factors, providing high clarity and explainability. The platform delivers AI-powered insights to trial sponsors, clinical research organizations, and biotechnology companies. These insights are used to inform protocol design, identify optimal patient subpopulations, determine effective dosage, enhance enrichment strategies, and improve inclusion/exclusion criteria, thereby increasing effect sizes and minimizing clinical trial risks.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2022-08-23 English
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Dr. Luca Pani as Chief Innovation and Regulatory Officer at Nurosene Health Inc. It focuses on management changes and does not contain financial data, regulatory filings, or report publications. There is no indication of financial results, audit information, or shareholder voting results. The content is clearly about a senior management appointment, which fits the Board/Management Information category.
2022-07-22 English
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (CFO) at Nurosene Health Inc. It contains no financial statements, no discussion of financial results, no regulatory filings, or voting results. It is an announcement about a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4512 characters, which is consistent with a typical management announcement press release. There is no indication that this is a report or a regulatory filing, nor does it contain financial data or earnings information.
2022-07-19 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of a new executive, Josh Spiegel, as President of a subsidiary of Nurosene Health Inc. It focuses on management changes and the background of the new appointee. There is no financial data, no report or filing attached, and no mention of voting results, dividends, or other financial or regulatory disclosures. The content clearly fits the category of announcements related to changes in senior management or the board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is sufficient and the content is detailed about the management appointment, supporting a high confidence score.
2022-07-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a Master Services Agreement between Nurosene Health Inc. and Denovo Biopharma LLC to support a clinical trial for treatment-resistant depression. It discusses the agreement details, the companies involved, and the clinical trial context. There are no financial statements, regulatory filings, voting results, or management discussions. The content is an announcement of a business agreement related to clinical trial technology, not a financial report or regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-07-06 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new Master Service Agreement between Nurosene Health Inc. and Taylored Biotherapeutics to evaluate clinical trial results using AI technology. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or operational report. It is a corporate announcement about a business collaboration and technology application. The document length is about 6,000 characters, which is relatively short and typical for a press release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement either, as it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2022-06-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.